6 Min Read
(In Jan 10 story, corrects paragraph 16 to say Pfizer and BioNTech halved 2020 output forecast in November, not December) Germany starts by sending vaccination teams to care homes Many vaccination centres stand idle Lack of supply, burdensome paperwork slow mobile teams Health minister targets 300,000 shots per day As in U.S., Spain, performance varies between states
BERLIN/DILLENBURG, Germany, Jan 10 (Reuters) - Proud of their national reputation for efficiency, Germans are growing increasingly frustrated by the slow rollout of a COVID-19 vaccine its scientists helped develop.
Scarce vaccine supply, cumbersome paperwork, a lack of healthcare staff and an aged and immobile population are hampering efforts to get early doses of a vaccine made by U.S.-based Pfizer and German partner BioNTech into the arms of the people.